DanielAaronPollyeaMD

PubMed

• 280 citations
  Acute myeloid leukemia, version 3.2019
  Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt
  Journal of the National Comprehensive Cancer Network. 2019-01-01
• 59 citations
  Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
  Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim Hien T. Dao, Emily A. Stevens
  Blood. 2019-09-12
• 412 citations
  Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML
  Julia E. Maxson, Jason Gotlib, Daniel A. Pollyea, Angela G. Fleischman, Anupriya Agarwal
  The New England Journal of Medicine. 2013-05-08

Journal Articles

• Randomized Comparison of Low Dose Cytarabine with or Without Glasdegib in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome  
  Daniel Pollyea, MD, Nature
• Venetoclax with Azacitidine Disrupts Energy Metabolism and Targets Leukemia Stem Cells in Patients with Acute Myeloid Leukemia  
  Daniel A Pollyea, Jonathan A Gutman, Enkhtsetseg Purev, Clayton Smith, Nature
• Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia  
  Brian A Jonas, Courtney D DiNardo, Olga Frankfurt, Daniel A Pollyea, Keith Pratz, Anthony Letai, Martha Arellano, Marina Konopleva, Hagop M Kantarjian, Blood
• Functional Genomic Landscape of Acute Myeloid Leukaemia  
  Marc M Loriaux, Christopher R Cogle, Patricia Kropf, Daniel A Pollyea, Uma Borate, Michael W Deininger, Nature
• Article Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells  
  Natalie J Serkova, Daniel A Pollyea, Enkhtsetseg Purev, ScienceDirect
• Next-Generation Sequencing and Eating of the Tree of Knowledge  
  Daniel Pollyea, MD, Clinical Cancer Research
• Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML  
  Daniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
• Join now to see all

Abstracts/Posters

• A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantat...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interim Results from the Phase I Deplethink Trial Evaluating the Infusion of a NKG2D CAR T-Cell Therapy Post a Non-Myeloablative Conditioning in Relapse or Refractory ...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Outcomes after Stem Cell Transplant in Older Patients with Acute Myeloid Leukemia Treated with Venetoclax-Based TherapiesClinically Relevant Abstract
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence of Serious Adverse Events, Pneumonitis, Infection and Sepsis in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphom...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes Following Allogeneic Stem Cell Transplantation for AML in First Completion Remission Are Comparable between MRD Negative Patients and MRD Positive Patients Re...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Inhibition of Fatty Acid Metabolism Re-Sensitizes Resistant Leukemia Stem Cells to Venetoclax with Azacitidine
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodyspl...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Venetoclax and Azacitidine for Older Newly Diagnosed Patients with Acute Myeloid Leukemia: A Single-Institution Pilot Study Using Measurable Residual Disease to Guide ...
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Developmental Plasticity of Acute Myeloid Leukemia Mediates Resistance to Venetoclax-Based Therapy
  Daniel A Pollyea, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Acute Myeloid Leukemia: Moving Beyond 7+3 
  60th American Society of Hematology Annual Meeting - 12/1/2018
• Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Tracking of AML-Associated Mutations Via Droplet Digital PCR Is Predictive of Outcomes Post-Transplant 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) T... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Join now to see all